Literature DB >> 21945530

The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains.

Amy L Robertson1, Mark A Bate, Ashley M Buckle, Stephen P Bottomley.   

Abstract

The nine polyglutamine (polyQ) neurodegenerative diseases are caused in part by a gain-of-function mechanism involving protein misfolding, the deposition of β-sheet-rich aggregates and neuronal toxicity. While previous experimental evidence suggests that the polyQ-induced misfolding mechanism is context dependent, the properties of the host protein, including the domain architecture and location of the polyQ tract, have not been investigated. Here, we use variants of a model polyQ-containing protein to systematically determine the effect of the location and number of flanking folded domains on polyQ-mediated aggregation. Our data indicate that when a pathological-length polyQ tract is present between two domains, it aggregates more slowly than the same-length tract in a terminal location within the protein. We also demonstrate that increasing the number of flanking domains decreases the polyQ protein's aggregation rate. Our experimental data, together with a bioinformatic analysis of all human proteins possessing polyQ tracts, suggest that repeat location and protein domain architecture affect the disease susceptibility of human polyQ proteins.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945530     DOI: 10.1016/j.jmb.2011.09.014

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  10 in total

Review 1.  Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.

Authors:  Adewale Adegbuyiro; Faezeh Sedighi; Albert W Pilkington; Sharon Groover; Justin Legleiter
Journal:  Biochemistry       Date:  2017-02-21       Impact factor: 3.162

2.  Polyalanine expansions drive a shift into α-helical clusters without amyloid-fibril formation.

Authors:  Saskia Polling; Angelique R Ormsby; Rebecca J Wood; Kristie Lee; Cheryl Shoubridge; James N Hughes; Paul Q Thomas; Michael D W Griffin; Andrew F Hill; Quill Bowden; Till Böcking; Danny M Hatters
Journal:  Nat Struct Mol Biol       Date:  2015-11-16       Impact factor: 15.369

Review 3.  Intrabodies as neuroprotective therapeutics.

Authors:  Anne Messer; Shubhada N Joshi
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

4.  Amyloid-like fibril formation by polyQ proteins: a critical balance between the polyQ length and the constraints imposed by the host protein.

Authors:  Natacha Scarafone; Coralie Pain; Anthony Fratamico; Gilles Gaspard; Nursel Yilmaz; Patrice Filée; Moreno Galleni; André Matagne; Mireille Dumoulin
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240

5.  Induction of functional Brm protein from Brm knockout mice.

Authors:  Kenneth W Thompson; Stefanie B Marquez; Li Lu; David Reisman
Journal:  Oncoscience       Date:  2015-04-18

6.  PolyQ 2.0: an improved version of PolyQ, a database of human polyglutamine proteins.

Authors:  Chen Li; Jeremy Nagel; Steve Androulakis; Jiangning Song; Ashley M Buckle
Journal:  Database (Oxford)       Date:  2016-03-15       Impact factor: 3.451

7.  In vitro aggregating β-lactamase-polyQ chimeras do not induce toxic effects in an in vivo Caenorhabditis elegans model.

Authors:  Roel Van Assche; Charline Borghgraef; Jonathan Vaneyck; Mireille Dumoulin; Liliane Schoofs; Liesbet Temmerman
Journal:  J Negat Results Biomed       Date:  2017-08-22

Review 8.  Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.

Authors:  Eiko N Minakawa; Yoshitaka Nagai
Journal:  Front Neurosci       Date:  2021-02-12       Impact factor: 4.677

Review 9.  Class A β-lactamases as versatile scaffolds to create hybrid enzymes: applications from basic research to medicine.

Authors:  Céline Huynen; Patrice Filée; André Matagne; Moreno Galleni; Mireille Dumoulin
Journal:  Biomed Res Int       Date:  2013-08-28       Impact factor: 3.411

10.  Conformational behavior and aggregation of ataxin-3 in SDS.

Authors:  Helen M Saunders; Victoria A Hughes; Roberto Cappai; Stephen P Bottomley
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.